IP Group sold a $5m stake to incoming shareholder Celltrion as part of a series A round for Iksuda, a spinout of Bath originally called Glythera.

Iksuda Therapeutics, a UK-based antibody drug conjugates developer spun out of University of Bath, has closed a $47m series A round that included a $5m stake sale by commercialisation firm IP Group to an incoming shareholder, biopharmaceutical firm Celltrion.
Celltrion co-led the round with Premier Partners, Mirae Asset and the latter’s subsidiaries.
IP Group owns a 19.4% undiluted stake in Iksuda following the deal.
Founded in 2007 as Glythera, Iksuda is working on antibody drug conjugates targeting…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in